<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: January 6, 2000
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5. OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing the appointment of Jay B. Zimmerman, M.Ed., as vice president of
clinical data management. The Press Release, dated January 6, 2000, is
attached as Exhibit 99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated January 6, 2000, announcing
the appointment of Jay B. Zimmerman, M.Ed., as vice president of
clinical data management.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ John Smolik
-----------------------
John Smolik, President
Date: January 6, 2000
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit Description
No.
<S> <C>
99 Press release of the Company, dated January 6, 2000,
announcing the appointment of Jay B. Zimmerman, M.Ed., as vice
president of clinical data management.
</TABLE>
<PAGE>
Exhibit 99
FOR IMMEDIATE RELEASE
PHOTOGEN TECHNOLOGIES APPOINTS JAY B. ZIMMERMAN, M.ED.,
VICE PRESIDENT, CLINICAL DATA MANAGEMENT
KNOXVILLE, TENN., JAN. 6, 2000 -- Photogen Technologies Inc. (NASDAQ: PHGN),
developers of non-invasive and minimally invasive diagnostics and therapies,
today announced the appointment of Jay B. Zimmerman, M.Ed., as vice president
of clinical data management.
Zimmerman, who has previously conducted major clinical trials for companies
such as Hoffmann LaRoche, Proctor & Gamble and Novartis Pharmaceuticals, as
well as pre-clinical trials for Sterling Pharmaceutical and Nycomed, will be
responsible for managing all imaging-related data for Photogen's clinical
trials. Zimmerman will be working with Dr. Gerald Wolf, Photogen's medical
director, in the Boston-based clinical development offices of the Company.
"With more than 13 years' experience in the field of hospital and clinical
research, most of which is directly related to medical imaging,
pharmaceutical development and clinical trials, Mr. Zimmerman will be a great
asset to our growing clinical development team," said John Smolik, Photogen
president and CEO.
"The pharmaceutical industry is beginning to realize the importance of using
imaging as a surrogate endpoint, as a valuable clinical trial tool to enhance
and hasten drug development," said Zimmerman. "I am pleased to be able to
contribute my imaging experience with a company that is making great
advancements in the area of light-based technologies."
Zimmerman's most recent position was with WorldCare Inc., as senior vice
president and COO. Previous to that position, he was administrative director
at Massachusetts General Hospital, initially with the Center for Imaging and
Pharmaceutical Research (CIPR) and more recently with the Department of Oral
& Maxillofacial Surgery. In those positions, Zimmerman administered a
research center and oversaw the design and implementation of CIPR's
computer-based imaging system.
Zimmerman holds a bachelor's of science from the University of South Carolina
and a master of education degree in administrative policy studies from the
University of Pittsburgh.
<PAGE>
ABOUT PHOTOGEN
Photogen Technologies, Inc. is a development-stage company focused on
creating therapeutic and diagnostic products based on its proprietary
multi-photon excitation and other related technologies. The company has
discovered new methods for using energy from lasers, X-rays or other sources
to activate photoactive agents within tissue sufficient to produce a range of
beneficial therapeutic and diagnostic outcomes. These technologies involve
methods, materials and devices that may be used to produce light or other
energy and photoactive agents and to destroy diseased cells, remove tissue or
identify and diagnose disease. Photogen has U.S. patents and additional
pending applications in the U.S. and elsewhere for certain of its proprietary
technology. The company has no diagnostic or therapeutic products at this
time.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks are qualified in their entirety by cautionary language
and risk factors set forth in the company's filings with the Securities and
Exchange Commission.
Media Contacts: Hilary Kaye or Joan Murray at Hilary Kaye Associates
(714) 426-0444 (PST) or [email protected].
Investor Relations Contact: Jonathan Fassberg at The Trout Group
(212) 477-9007 (EST) or [email protected].
###
